FIELD: pharmaceutical industry.
SUBSTANCE: group of inventions relates to the field of chemical and pharmaceutical industry and medicine and concerns a new pharmaceutical composition of favipiravir, a drug based on it and the use of this composition. A pharmaceutical composition is proposed that exhibits preventive and/or therapeutic antiviral activity, containing therapeutically effective amounts of favipiravir and at least one hydrate of a proteinogenic amino acid and/or its pharmaceutically acceptable salt, where the mass ratio of favipiravir to the hydrate of a proteinogenic amino acid and/or its pharmaceutically acceptable salt is 1.0:0.1-1.0:1.1, respectively. It is also proposed to use the above pharmaceutical composition to obtain a drug for the treatment and/or prevention of viral infections and a drug exhibiting preventive and/or therapeutic antiviral activity, containing the above pharmaceutical composition and at least one pharmaceutically acceptable excipient.
EFFECT: use of favipiravir with hydrates of proteinogenic amino acids or their salts at certain mass ratios ensures high stability of the compositions, as well as a high rate of dissolution of the composition in the form of powder or lyophilizate in a pharmaceutically acceptable solvent.
63 cl, 4 dwg, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING FAVIPIRAVIR AND AN AMINO ACID, MEDICINAL PRODUCT CONTAINING SAID COMPOSITION, AND APPLICATION THEREOF FOR TREATING AND/OR PREVENTING VIRAL INFECTIONS | 2021 |
|
RU2783282C1 |
| ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING FAVIPIRAVIR AND AMINO ACID, DRUG CONTAINING IT, AS WELL AS THEIR USE FOR TREATING AND/OR PREVENTING VIRAL INFECTIONS | 2022 |
|
RU2814927C1 |
| NOVEL FORMS OF (1R,2S,5S)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOPYRROLIDIN-3-YL]ETHYL]-3-[(2S)-3,3-DIMETHYL-2-[(2,2,2-TRIFLUOROACETYL)AMINO]BUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE | 2023 |
|
RU2827154C1 |
| NOVEL FORMS OF (1R,2S,5S)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOPYRROLIDIN-3-YL]ETHYL]-3-[(2S)-3,3-DIMETHYL-2-[(2,2,2-TRIFLUOROACETYL)AMINO]BUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE | 2023 |
|
RU2827157C1 |
| NOVEL FORMS OF (1R,2S,5S)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOPYRROLIDIN-3-YL]ETHYL]-3-[(2S)-3,3-DIMETHYL-2-[(2,2,2-TRIFLUOROACETYL)AMINO]BUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE | 2023 |
|
RU2827357C1 |
| NOVEL FORMS OF (1R,2S,5S)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOPYRROLIDIN-3-YL]ETHYL]-3-[(2S)-3,3-DIMETHYL-2-[(2,2,2-TRIFLUOROACETYL)AMINO]BUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE | 2023 |
|
RU2827158C1 |
| NOVEL FORMS OF (1R,2S,5S)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOPYRROLIDIN-3-YL]ETHYL]-3-[(2S)-3,3-DIMETHYL-2-[(2,2,2-TRIFLUOROACETYL)AMINO]BUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE | 2023 |
|
RU2827358C1 |
| METHOD OF PRODUCING NOVEL DERIVATIVES OF FAVIPIRAVIR | 2023 |
|
RU2828875C1 |
| NEW COMBINED PHARMACEUTICAL COMPOSITION AND MEDICINAL PRODUCT FOR TREATMENT OF CORONAVIRUS INFECTION | 2022 |
|
RU2806643C1 |
| NEW AZABICYCLOHEXANE DERIVATIVES | 2023 |
|
RU2811800C1 |
